A064550 Stock Overview
Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A064550 from our risk checks.
Bioneer Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩19,720.00 |
| 52 Week High | ₩39,100.00 |
| 52 Week Low | ₩19,250.00 |
| Beta | -1.09 |
| 11 Month Change | -18.51% |
| 3 Month Change | -34.27% |
| 1 Year Change | -36.28% |
| 33 Year Change | -61.18% |
| 5 Year Change | 200.61% |
| Change since IPO | 41.87% |
Recent News & Updates
Investors Don't See Light At End Of Bioneer Corporation's (KOSDAQ:064550) Tunnel And Push Stock Down 26%
Nov 14
Bioneer Corporation's (KOSDAQ:064550) 27% Dip In Price Shows Sentiment Is Matching Revenues
Sep 06Bioneer Corporation's (KOSDAQ:064550) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Jul 11Lacklustre Performance Is Driving Bioneer Corporation's (KOSDAQ:064550) Low P/S
Mar 06Recent updates
Investors Don't See Light At End Of Bioneer Corporation's (KOSDAQ:064550) Tunnel And Push Stock Down 26%
Nov 14Bioneer Corporation's (KOSDAQ:064550) 27% Dip In Price Shows Sentiment Is Matching Revenues
Sep 06Bioneer Corporation's (KOSDAQ:064550) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Jul 11Lacklustre Performance Is Driving Bioneer Corporation's (KOSDAQ:064550) Low P/S
Mar 06Bioneer (KOSDAQ:064550) Seems To Use Debt Quite Sensibly
Mar 25Bioneer Corporation's (KOSDAQ:064550) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 15Investors Who Bought Bioneer (KOSDAQ:064550) Shares A Year Ago Are Now Up 166%
Jan 20
Is Bioneer (KOSDAQ:064550) A Risky Investment?
Dec 24Here's Why We Think Bioneer's (KOSDAQ:064550) Statutory Earnings Might Be Conservative
Nov 28Shareholder Returns
| A064550 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.2% | -3.0% | 2.3% |
| 1Y | -36.3% | 22.4% | -3.8% |
Return vs Industry: A064550 underperformed the KR Biotechs industry which returned 22.4% over the past year.
Return vs Market: A064550 underperformed the KR Market which returned -3.8% over the past year.
Price Volatility
| A064550 volatility | |
|---|---|
| A064550 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A064550 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A064550's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 561 | Han-Oh Park | www.bioneer.co.kr |
Bioneer Corporation operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer and solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide function, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, and electrophoresis. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal, aquatic-bio, mosquito-borne, and plant diseases, as well as food safety, human pathogen, and nano-bio products.
Bioneer Corporation Fundamentals Summary
| A064550 fundamental statistics | |
|---|---|
| Market cap | ₩515.95b |
| Earnings (TTM) | -₩16.20b |
| Revenue (TTM) | ₩295.52b |
1.7x
P/S Ratio-31.4x
P/E RatioIs A064550 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A064550 income statement (TTM) | |
|---|---|
| Revenue | ₩295.52b |
| Cost of Revenue | ₩69.99b |
| Gross Profit | ₩225.52b |
| Other Expenses | ₩241.72b |
| Earnings | -₩16.20b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -627.49 |
| Gross Margin | 76.32% |
| Net Profit Margin | -5.48% |
| Debt/Equity Ratio | 22.9% |
How did A064550 perform over the long term?
See historical performance and comparison